WO2000053216A3 - Use of casb616 polypeptides and polynucleotides for cancer treatment - Google Patents

Use of casb616 polypeptides and polynucleotides for cancer treatment Download PDF

Info

Publication number
WO2000053216A3
WO2000053216A3 PCT/EP2000/001587 EP0001587W WO0053216A3 WO 2000053216 A3 WO2000053216 A3 WO 2000053216A3 EP 0001587 W EP0001587 W EP 0001587W WO 0053216 A3 WO0053216 A3 WO 0053216A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
cancer treatment
casb616
polypeptides
casb616 polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/001587
Other languages
French (fr)
Other versions
WO2000053216A2 (en
Inventor
Y De Bassols Carlota Vinals
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0008784-0A priority Critical patent/BR0008784A/en
Priority to CA002362370A priority patent/CA2362370A1/en
Priority to NZ513837A priority patent/NZ513837A/en
Priority to EP00907633A priority patent/EP1162993B1/en
Priority to DE60019273T priority patent/DE60019273T2/en
Priority to AU29153/00A priority patent/AU766789B2/en
Priority to IL14504600A priority patent/IL145046A0/en
Priority to KR1020017011300A priority patent/KR20010102507A/en
Priority to SI200030661T priority patent/SI1162993T1/en
Priority to JP2000603705A priority patent/JP2002538218A/en
Priority to HK02103796.8A priority patent/HK1043729B/en
Priority to AT00907633T priority patent/ATE292472T1/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to DK00907633T priority patent/DK1162993T3/en
Publication of WO2000053216A2 publication Critical patent/WO2000053216A2/en
Publication of WO2000053216A3 publication Critical patent/WO2000053216A3/en
Priority to NO20014292A priority patent/NO20014292L/en
Anticipated expiration legal-status Critical
Priority to US10/984,521 priority patent/US20050129717A1/en
Priority to CY20051100614T priority patent/CY1105585T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Use of CASB616 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colon cancers, autoimmune diseases, and related conditions.
PCT/EP2000/001587 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment Ceased WO2000053216A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
HK02103796.8A HK1043729B (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
NZ513837A NZ513837A (en) 1999-03-05 2000-02-28 Methods for using CASB616 polypeptides and nucleotides to assist in the treatment of cancer
EP00907633A EP1162993B1 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
DE60019273T DE60019273T2 (en) 1999-03-05 2000-02-28 USE OF CASB616 POLYPEPTIDES AND POLYNUCLEOTIDES FOR CANCER TREATMENT
AU29153/00A AU766789B2 (en) 1999-03-05 2000-02-28 Novel uses
IL14504600A IL145046A0 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
KR1020017011300A KR20010102507A (en) 1999-03-05 2000-02-28 Novel uses
SI200030661T SI1162993T1 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
JP2000603705A JP2002538218A (en) 1999-03-05 2000-02-28 New usage
BR0008784-0A BR0008784A (en) 1999-03-05 2000-02-28 Uses
CA002362370A CA2362370A1 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment
AT00907633T ATE292472T1 (en) 1999-03-05 2000-02-28 USE OF CASB616 POLYPEPTIDES AND POLYNUCLEOTIDES FOR CANCER TREATMENT
DK00907633T DK1162993T3 (en) 1999-03-05 2000-02-28 Use of CASB616 polypeptides and polynucleotides for cancer treatment
NO20014292A NO20014292L (en) 1999-03-05 2001-09-04 New uses
US10/984,521 US20050129717A1 (en) 1999-03-05 2004-11-09 Novel uses
CY20051100614T CY1105585T1 (en) 1999-03-05 2005-05-18 USE OF CASB616 POLYPEPTIDES AND POLYNUCLEOTIDES FOR THE TREATMENT OF CANCER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905124.5A GB9905124D0 (en) 1999-03-05 1999-03-05 Novel compounds
GB9905124.5 1999-03-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/984,521 Division US20050129717A1 (en) 1999-03-05 2004-11-09 Novel uses

Publications (2)

Publication Number Publication Date
WO2000053216A2 WO2000053216A2 (en) 2000-09-14
WO2000053216A3 true WO2000053216A3 (en) 2001-01-11

Family

ID=10849064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001587 Ceased WO2000053216A2 (en) 1999-03-05 2000-02-28 Use of casb616 polypeptides and polynucleotides for cancer treatment

Country Status (23)

Country Link
US (1) US20050129717A1 (en)
EP (2) EP1162993B1 (en)
JP (1) JP2002538218A (en)
KR (1) KR20010102507A (en)
CN (1) CN1374869A (en)
AT (1) ATE292472T1 (en)
AU (1) AU766789B2 (en)
BR (1) BR0008784A (en)
CA (1) CA2362370A1 (en)
CY (1) CY1105585T1 (en)
CZ (1) CZ20013189A3 (en)
DE (1) DE60019273T2 (en)
ES (1) ES2238026T3 (en)
GB (1) GB9905124D0 (en)
HK (1) HK1043729B (en)
HU (1) HUP0200186A2 (en)
IL (1) IL145046A0 (en)
NO (1) NO20014292L (en)
NZ (1) NZ513837A (en)
PL (1) PL354143A1 (en)
PT (1) PT1162993E (en)
TR (1) TR200102577T2 (en)
WO (1) WO2000053216A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271621A1 (en) * 2000-06-28 2002-01-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
SI2266603T1 (en) * 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumour vaccines
CN1446583A (en) * 2002-11-29 2003-10-08 帕弗瑞生物技术(北京)有限公司 Composition, preparation and application scheme of tumor immunological therapy and preventative vaccine
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
SI2528625T1 (en) 2010-04-15 2013-11-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
BR112014009050B1 (en) 2011-10-14 2022-06-21 Medimmune Limited Pyrrolbenzodiazepine antibody-drug conjugate, pharmaceutical composition comprising the same, as well as pyrrolebenzodiazepine compounds
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HRP20182129T1 (en) 2012-10-12 2019-02-08 Adc Therapeutics Sa CONJUGATES ANTIBODY - PIROLOBENZODIAZEPINE
RS57694B1 (en) 2012-10-12 2018-11-30 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
JP6392765B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
MX338711B (en) 2012-10-12 2016-04-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
CN105189507A (en) 2012-12-21 2015-12-23 斯皮罗根有限公司 Pyrrolobenzodiazepines and conjugates thereof
CN110627797A (en) 2012-12-21 2019-12-31 麦迪穆有限责任公司 Asymmetric pyrrolobenzodiazepine dimers for the treatment of proliferative and autoimmune diseases
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX362970B (en) 2013-03-13 2019-02-28 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof.
TWI680766B (en) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 Pyrrolobenzodiazepines and conjugates thereof
BR112016002829A2 (en) 2013-08-12 2017-09-19 Genentech Inc COMPOUND AND PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION, CANCER TREATMENT METHOD, CANCER TREATMENT KIT, DRUG LINKER INTERMEDIATE, CBI DIMER DRUG MOUNT AND COMPOUND
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
JP6671292B2 (en) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド Peptidomimetic compounds and antibody-drug conjugates thereof
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
CN107073136A (en) 2014-09-17 2017-08-18 健泰科生物技术公司 Pyrrolobenzodiazepines Zhuo and its antibody disulphide conjugate
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CR20180243A (en) 2015-10-02 2018-07-31 Genentech Inc PIRROLOBENZODIAZEPIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (en) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 PROTAC antibody conjugates and methods of use thereof
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (en) 2016-08-11 2024-04-05 基因泰克公司 Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (en) 2017-02-08 2021-06-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (en) 2017-04-18 2021-04-02 免疫医疗有限公司 Pyrrolobenzodiazepine* conjugates
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (en) 2017-08-18 2021-06-30 메디뮨 리미티드 pyrrolobenzodiazepine conjugate
EP3684773B1 (en) 2017-09-20 2026-04-29 pH Pharma Co., Ltd. Thailanstatin analogs
US11068545B2 (en) 2017-11-17 2021-07-20 Battelle Memorial Institute Spatial identification of assets using n-dimensional asset identifiers
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP7708662B2 (en) 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Conjugated chemical degraders and methods of use
JP2022513198A (en) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN113631560B (en) 2019-03-15 2025-02-18 麦迪穆有限责任公司 Azetidine benzodiazepine dimers and conjugates containing them for treating cancer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
KR20260012304A (en) 2023-04-17 2026-01-26 피크 바이오, 인크. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
CN120324603B (en) * 2025-04-28 2025-12-23 中奥生物医药技术(广东)有限公司 Application of Caerin polypeptide combined dendritic cell vaccine in preparation of medicine for treating breast cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE293989T1 (en) * 1998-11-20 2005-05-15 Genentech Inc USE OF EPH RECEPTOR ANTAGONISTS AND AGONISTS FOR THE TREATMENT OF VASCULAR DISEASES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN YING ET AL: "DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.", CANCER RESEARCH, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1965 - 1971, XP002149613, ISSN: 0008-5472 *
FOX GARY M ET AL: "CDNA cloning and tissue distribution of five human EPH-like receptor protein-tyrosine kinases.", ONCOGENE, vol. 10, no. 5, 1995, pages 897 - 905, XP000946743, ISSN: 0950-9232 *
IKEGAKI NAOHIKO ET AL: "Molecular characterization and chromosomal localization of DRT (EPHT3): A developmentally regulated human protein-tyrosine kinase gene of the EPH family.", HUMAN MOLECULAR GENETICS, vol. 4, no. 11, 1995, pages 2033 - 2045, XP000946771, ISSN: 0964-6906 *
IWASE T ET AL: "IDENTIFICATION OF PROTEIN-TYROSINE KINASE GENES PREFERENTIALLY EXPRESSED IN EMBRYO STOMACH AND GASTRIC CANCER", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 194, no. 2, 30 July 1993 (1993-07-30), pages 698 - 705, XP002014925, ISSN: 0006-291X *
KIYOKAWA E ET AL: "OVEREXPRESSION OF ERK AN EPH FAMILY RECEPTOR PROTEIN TYROSINE KINASE IN VARIOUS HUMAN TUMORS", CANCER RESEARCH,US,AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 54, 15 July 1994 (1994-07-15), pages 3645 - 3650, XP002070092, ISSN: 0008-5472 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Also Published As

Publication number Publication date
AU766789B2 (en) 2003-10-23
ATE292472T1 (en) 2005-04-15
PL354143A1 (en) 2003-12-29
JP2002538218A (en) 2002-11-12
HUP0200186A2 (en) 2002-05-29
ES2238026T3 (en) 2005-08-16
TR200102577T2 (en) 2004-09-21
CY1105585T1 (en) 2010-07-28
HK1043729B (en) 2005-11-04
EP1162993B1 (en) 2005-04-06
AU2915300A (en) 2000-09-28
GB9905124D0 (en) 1999-04-28
CN1374869A (en) 2002-10-16
DE60019273D1 (en) 2005-05-12
IL145046A0 (en) 2002-06-30
NO20014292L (en) 2001-10-29
EP1466616A2 (en) 2004-10-13
EP1162993A2 (en) 2001-12-19
PT1162993E (en) 2005-06-30
NZ513837A (en) 2003-02-28
HK1043729A1 (en) 2002-09-27
CZ20013189A3 (en) 2002-02-13
BR0008784A (en) 2001-12-26
US20050129717A1 (en) 2005-06-16
DE60019273T2 (en) 2006-01-19
NO20014292D0 (en) 2001-09-04
CA2362370A1 (en) 2000-09-14
WO2000053216A2 (en) 2000-09-14
KR20010102507A (en) 2001-11-15
EP1466616A3 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
EP1466616A3 (en) Use of CASB616 polypeptides and polynucleotides for cancer treatment
AU3617700A (en) Human colon cancer associated gene sequences and polypeptides
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
ZA200205191B (en) LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.
SI1716853T1 (en) Treatment of cancers of the human body using ET743
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
AU2002246922A1 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2000053748A3 (en) Casb618 polynucleotides and polypeptides and their use
MXPA01011720A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods.
WO2000058460A3 (en) Casb619 involved in colon cancers
WO2001062925A3 (en) 103p2d6: tissue specific protein highly expressed in various cancers
EP1250145A4 (en) C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
AU5618700A (en) Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
AU2001249608A1 (en) Bladder cancer-specific peptides for diagnosis and therapy
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
WO2000043509A3 (en) Polynucleotides and their applications in diagnostics
ZA991783B (en) Therapeutic treatment for autoimmune diseases.
WO2001023417A3 (en) Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses
AU2002365104A1 (en) Method for the diagnosis of breast cancer diseases, associated peptides and the uses thereof
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
AU1439401A (en) Diagnosis and treatment of cancer using star polypeptides and polynucleotides
AU2001247560A1 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
WO2003057240A3 (en) Treatment and diagnosis of af4-dependant diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00807172.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 145046

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000907633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 513837

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2362370

Country of ref document: CA

Ref document number: 2362370

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/1221/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2001-3189

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2000 603705

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017011300

Country of ref document: KR

Ref document number: PA/a/2001/008968

Country of ref document: MX

Ref document number: 2001/02577

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 29153/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020017011300

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000907633

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09914883

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2001-3189

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 29153/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000907633

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017011300

Country of ref document: KR